Activation of extracellular signal-regulated kinase‑1/2 in blood mononuclear cells of patients with diabetes and autoimmune thyroiditis
pdf (Українська)

Keywords

peripheral blood mononuclear cells, extracellular signal-regulated kinase‑1/2, type 1 and type 2 diabetes, cancer, autoimmune thyroiditis.

How to Cite

Pushkarev, V., Sokolova, L., Kovzun, O., Cherviakova, S., Vatseba, T., Pushkarev, V., & Tronko, M. (2020). Activation of extracellular signal-regulated kinase‑1/2 in blood mononuclear cells of patients with diabetes and autoimmune thyroiditis. Endokrynologia, 25(1), 49-52. https://doi.org/10.31793/1680-1466.2020.25-1.49

Abstract

The peripheral blood mononuclear cells (PBMC) mainly includes monocytes and lymphocytes involved in the development of diabetes mellitus and other autoimmune diseases. Ret/Ras/Raf/MEK/ERK is a signaling cascade that controls cellular processes such as proliferation, survival, angiogenesis, cell growth and motility. The aim of the work was to study the activation of the main effector protein kinase of this cascade — ЕRК1/2 in PBMC of patients with diabetes and autoimmune (Hashimoto’s) thyroiditis. Material and methods. The material of this work was the blood of healthy subjects, patients with type 2 diabetes, with type 2 diabetes and AIT, with type 2 diabetes and cancer (papillary thyroid carcinoma), with type 1 diabetes, with type 1 diabetes and AIT. Enzyme-linked immunosorbent assay kit 85-86012 («Invitrogen», USA) were used to determine the amount of phospho-ЕRК1/2 (p-Thr202/Thr204, Thr185/ Tyr187, respectively). Results. Patients were divided into 6 groups: 1 — control — healthy subjects, representative for age and BMI, 2 — patients with type 2 diabetes, 3 — patients with type 2 diabetes and AIT, 4 — patients with type 2 diabetes and thyroid cancer, 5 — patients with type 1 diabetes, 6 — patients with type 1 diabetes and AIT. It was shown that activation of ЕRК1/2 in PBMC of patients with type 2 diabetes and cancer was not observed, while in patients with type 1 diabetes or autoimmune thyroiditis it increased significantly. However, in patients with type 1 diabetes with autoimmune thyroiditis, the activation of ЕRК1/2 in PBMC decreased to a control level, which can be explained by the competition between the two autoimmune processes for common signaling pathways. Conclusion. In PBMC of patients with autoimmune diseases (type 1 diabetes or AIT), MAPK/ERK cascade is activated.

https://doi.org/10.31793/1680-1466.2020.25-1.49
pdf (Українська)

References

Subramanian V, Ferrante A Jr. Obesity, inflammation, and macrophages. Nestle Nutr Workshop Ser Paediatr Program. 2009;63:151-59.

Тронько НД, Пушкарев ВМ, Соколова ЛК, Пушкарев ВВ, Ковзун ЕИ. Молекулярные механизмы патогенеза сахарного диабета и его осложнений. К.: Издательский дом Медкнига, 2018. 264 с. (Tronko ND, Pushkarev VM, Sokolova LC, Pushkarev VV, Kovzun EI. Molecular mechanisms of the pathogenesis of diabetes mellitus and its complications. K .: Medknig Publishing House, 2018.264 p.).

Buzdugă CM, Costea CF, Dumitrescu GF, Turliuc MD, Bogdănici CM, Cucu A, et al. Cytological, histopathological and immunological aspects of autoimmune thyroiditis: a review. Rom J Morphol Embryol. 2017;58(3):731-8.

Iddah MA, Macharia BN. Autoimmune thyroid disorders. ISRN Endocrinol. 2013;2013:509764.

Ajjan RA, Weetman AP. The Pathogenesis of Hashimoto’s Thyroiditis: further developments in our understanding. Horm Metab Res. 2015;47(10):702-10.

Mendoza M, Er E, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci. 2011;36(6):320-8.

Wortzel I, Seger R. The ERK cascade: distinct functions within various subcellular organelles. Genes Cancer. 2011;2(3):195-209.

Vatseba TS, Sokolova LK, Pushkarev VV, Kovzun OI, Guda BB, Pushkarev VM, et al. Activation of the PI3K/Akt/mTOR/p70S6K1 signaling cascade in the mononuclear cells of peripheral blood: association with insulin and insulin-like growth factor levels in the blood of patients with cancer and diabetes. Cytol Genet. 2019;53(6):489-93.

Delves PJ, Martin SJ, Burton DR, Roitt IM. Roitt’s Essential Immunology, 13th ed. Wiley and Sons, Ltd, 2017. 556 p.

Arthur JS, Ley SC. Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol. 2013;13:679-92.

Pushkarev V, Guda B, Pushkarev V, Tronko N. Oncogene toxicity in thyroid carcinomas and other types of tumors. Cytol Genet. 2018;521(52):54-61.

Гуда ББ, Пушкарьов ВВ, Ковзун ОІ, Пушкарьов ВМ, Тронько МД. Токсичність МАРК у карциномах ЩЗ. Механізми пригнічення сигнального каскаду. Огляд літератури та власних даних. Шпитальна хірургія. 2019;3:84-96. (Guda BB, Pushkaryov BB, Kovzun OI, Pushkaryov VM, Tronko MD. MARK toxicity in thyroid carcinomas. Mechanisms of signal cascade suppression. Literature and personal data review. Hospital surgery. 2019;3:84-96.).

Park JI. Growth arrest signaling of the Raf/MEK/ERK pathway in cancer. Front Biol (Beijing). 2014;9(2):95-103.

Ciliberti MG, Albenzio M, Inghese C, Santillo A, Marino R, Sevi A, et al. Peripheral blood mononuclear cell proliferation and cytokine production in sheep as affected by cortisol level and duration of stress. J Dairy Sci. 2017;100(1):750-6.

Zheng Q, Xu J, Gao H, Tao R, Li W, Shang S, et al. Receptor expression and responsiveness of human peripheral blood mononuclear cells to a human cytomegalovirus encoded CC chemokine. Braz J Infect Dis. 2015;19(4):403-9.

Downloads

Download data is not yet available.